75000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 75010 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION link:presentationLink link:calculationLink link:definitionLink 75020 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 75030 - Statement - CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 75040 - Statement - CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS 3 link:presentationLink link:calculationLink link:definitionLink 75050 - Statement - CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS 35 link:presentationLink link:calculationLink link:definitionLink 75060 - Statement - CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS 36 link:presentationLink link:calculationLink link:definitionLink 75070 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 75080 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 995457 - Disclosure - Cybersecurity Risk Management, Strategy and Governance link:presentationLink link:calculationLink link:definitionLink 995467 - Disclosure - General information link:presentationLink link:calculationLink link:definitionLink 995477 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995487 - Disclosure - Critical estimates and judgments link:presentationLink link:calculationLink link:definitionLink 995497 - Disclosure - Revenue from contracts with customers link:presentationLink link:calculationLink link:definitionLink 995507 - Disclosure - Key management compensation link:presentationLink link:calculationLink link:definitionLink 995517 - Disclosure - Income tax link:presentationLink link:calculationLink link:definitionLink 995527 - Disclosure - Loss per share link:presentationLink link:calculationLink link:definitionLink 995537 - Disclosure - VAT Receivable and Tax Credits link:presentationLink link:calculationLink link:definitionLink 995547 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 995557 - Disclosure - Prepaid Expenses and Deposits link:presentationLink link:calculationLink link:definitionLink 995567 - Disclosure - Property, plant & equipment, net link:presentationLink link:calculationLink link:definitionLink 995577 - Disclosure - Intangible Software, net link:presentationLink link:calculationLink link:definitionLink 995587 - Disclosure - Loan Payable link:presentationLink link:calculationLink link:definitionLink 995597 - Disclosure - Accounts receivable link:presentationLink link:calculationLink link:definitionLink 995607 - Disclosure - Cash and cash equivalents link:presentationLink link:calculationLink link:definitionLink 995617 - Disclosure - Accounts payable and accrued liabilities link:presentationLink link:calculationLink link:definitionLink 995627 - Disclosure - Deferred Revenue link:presentationLink link:calculationLink link:definitionLink 995637 - Disclosure - Commitments link:presentationLink link:calculationLink link:definitionLink 995647 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 995657 - Disclosure - Related party transactions link:presentationLink link:calculationLink link:definitionLink 995667 - Disclosure - Risk management overview link:presentationLink link:calculationLink link:definitionLink 995677 - Disclosure - Stockholder's equity link:presentationLink link:calculationLink link:definitionLink 995687 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995697 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995707 - Disclosure - General Information (Tables) link:presentationLink link:calculationLink link:definitionLink 995717 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995727 - Disclosure - Revenue from Contracts with Customers (Tables) link:presentationLink link:calculationLink link:definitionLink 995737 - Disclosure - Income tax (Tables) link:presentationLink link:calculationLink link:definitionLink 995747 - Disclosure - Loss per share (Tables) link:presentationLink link:calculationLink link:definitionLink 995757 - Disclosure - VAT Receivable and Tax Credits (Tables) link:presentationLink link:calculationLink link:definitionLink 995767 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 995777 - Disclosure - Prepaid Expenses and Deposits (Tables) link:presentationLink link:calculationLink link:definitionLink 995787 - Disclosure - Property, Plant & Equipment, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 995797 - Disclosure - Intangible Software, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 995807 - Disclosure - Accounts Receivable (Tables) link:presentationLink link:calculationLink link:definitionLink 995817 - Disclosure - Cash and Cash Equivalents (Tables) link:presentationLink link:calculationLink link:definitionLink 995827 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 995837 - Disclosure - Deferred Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 995847 - Disclosure - Commitments (Tables) link:presentationLink link:calculationLink link:definitionLink 995857 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 995867 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 995877 - Disclosure - Risk Management Overview (Tables) link:presentationLink link:calculationLink link:definitionLink 995887 - Disclosure - Stockholder's equity (Tables) link:presentationLink link:calculationLink link:definitionLink 995897 - Disclosure - General Information - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995907 - Disclosure - Summary of Significant Accounting Policies - Summary of Consolidated Operating Subsidiaries (Details) link:presentationLink link:calculationLink link:definitionLink 995917 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995927 - Disclosure - Summary of Significant Accounting Policies - Functional and Presentation Currency (Details) link:presentationLink link:calculationLink link:definitionLink 995937 - Disclosure - Summary of Significant Accounting Policies - Disclosure of Effect of Changes in Foreign Exchange Rates (Details) link:presentationLink link:calculationLink link:definitionLink 995947 - Disclosure - Summary of Significant Accounting Policies - Disclosure of Estimated Useful Lives of Property Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 995957 - Disclosure - Revenue from Contracts with Customers - Schedule of Disaggregation of Revenue from Contracts with Customers (Details) link:presentationLink link:calculationLink link:definitionLink 995967 - Disclosure - Revenue from Contracts with Customers - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995977 - Disclosure - Key Management Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995987 - Disclosure - Income Tax - Reconciliation of Income Taxes at Statutory Rates (Details) link:presentationLink link:calculationLink link:definitionLink 995997 - Disclosure - Income Tax - Summary of Net Deferred Tax Asset (Liability) (Details) link:presentationLink link:calculationLink link:definitionLink 996007 - Disclosure - Income Tax - Summary of Temporary Differences (Details) link:presentationLink link:calculationLink link:definitionLink 996017 - Disclosure - Income Tax - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996027 - Disclosure - Loss per share - Schedule of Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 996037 - Disclosure - Loss per share - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996047 - Disclosure - Loss per share - Schedule of Diluted Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 996057 - Disclosure - VAT Receivable and Tax Credits - Summary of VAT Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 996067 - Disclosure - VAT Receivable and Tax Credits - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996077 - Disclosure - Inventories - Summary of Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 996087 - Disclosure - Inventories - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996097 - Disclosure - Prepaid Expenses and Deposits - Summary of Prepaid Expenses and Deposits (Details) link:presentationLink link:calculationLink link:definitionLink 996107 - Disclosure - Property, Plant & Equipment, Net - Summary of Property, Plant & Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 996117 - Disclosure - Property, Plant & Equipment, Net - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996127 - Disclosure - Intangible Software, Net - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996137 - Disclosure - Intangible Software, Net - Summary of Intangible Software (Details) link:presentationLink link:calculationLink link:definitionLink 996147 - Disclosure - Intangible Software, Net - Schedule of Software Development Costs (Details) link:presentationLink link:calculationLink link:definitionLink 996157 - Disclosure - Accounts Receivable - Summary of Accounts Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 996167 - Disclosure - Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details) link:presentationLink link:calculationLink link:definitionLink 996177 - Disclosure - Cash and Cash Equivalents - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996187 - Disclosure - Accounts Payable and Accrued Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 996197 - Disclosure - Accounts Payable and Accrued Liabilities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996207 - Disclosure - Loan Payable - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996217 - Disclosure - Deferred Revenue - Summary of Deferred Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 996227 - Disclosure - Deferred Revenue - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996237 - Disclosure - Contingent Liabilities and Contingent Assets - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996247 - Disclosure - Commitments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996257 - Disclosure - Leases - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996267 - Disclosure - Leases - Schedule of Annual Rent (Details) link:presentationLink link:calculationLink link:definitionLink 996277 - Disclosure - Leases - Summary of Right of Use Assets Activity (Details) link:presentationLink link:calculationLink link:definitionLink 996287 - Disclosure - Leases - Summary of Lease Liability Activity (Details) link:presentationLink link:calculationLink link:definitionLink 996297 - Disclosure - Leases - Summary of Maturity of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 996307 - Disclosure - Related Party Transactions - Summary of Related Party Payables (Details) link:presentationLink link:calculationLink link:definitionLink 996317 - Disclosure - Related party transactions - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996327 - Disclosure - Related Party Transactions - Summary of Related Party Compensation for Officers and Directors (Details) link:presentationLink link:calculationLink link:definitionLink 996337 - Disclosure - Risk Management Overview - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996347 - Disclosure - Risk Management Overview - Disclosure of Monetary Assets and Liabilities Denominated In Foreign Currencies (Details) link:presentationLink link:calculationLink link:definitionLink 996357 - Disclosure - Stockholder's Equity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996367 - Disclosure - Stockholder's Equity - Summary of Activity Related to Outstanding Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 996377 - Disclosure - Stockholder's Equity - Summary of Calculation of Fair Value of Awards using Black-Scholes Option-Pricing Model Affected by Stock price on Date of Grant as well as Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 996387 - Disclosure - Stockholder's Equity - Summary of Status of Outstanding Stock Options and Changes (Details) link:presentationLink link:calculationLink link:definitionLink 996397 - Disclosure - Subsequent Events - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink Lease expense Cash outflow for leases Payment of lease liabilities Disclosure of financial assets [table] Percentage of capital owned. Percentage of capital owned Percentage of capital owned 2022 Plan Two Thousand and Twenty Two Plan [Member] 2022 plan member. Disclosure of changes in accounting policies [text block] Summary of Significant Accounting Policies Maximum period of net operating losses carried forward. Maximum period of net operating losses carried forward Maximum period of net operating losses carried forward Contractual maturities of trade payables. Contractual maturities of trade payables Contractual maturities of trade payables Test kit sales [Member] Test kit sales. Test Kit Sales Intangible assets Intangible assets other than goodwill deferred tax assets. Intangible assets other than goodwill deferred tax assets Ms. Anne Foster, mother of Mr. James Foster Ms Anne Foster mother Of Mr James Foster. Ms Anne Foster mother Of Mr James Foster [Member] At-the-Market offering. At-the-Market Offering [Member] At-the-Market Offering New Shanghai Lease New Shanghai lease. New Shanghai Lease [Member] Top of Range Top of range [member] Entity Incorporation, State or Country Code Virax biolabs hkco limited. Virax Biolabs HKCo Limited [Member] Virax Biolabs HKCo Limited Entity Current Reporting Status VIRGIN ISLANDS, BRITISH British Virgin Island Accrued bonuses Accrued Bonus Accrued bonus. Unrealized Gain/Loss Deferred Tax Assets Unrealized gain/loss deferred tax assets Unrealized gain/loss Number of remaining lease agreement. Number of remaining lease agreement Classes of property, plant and equipment [axis] Payments of lease liabilities Payments of lease liabilities, classified as financing activities Lease payments Non-current lease liabilities Non-current lease liabilities Disclosure of detailed information about leases. Disclosure of detailed information about leases [line items] Product and Service [Axis] Expected term Option life, share options granted Document Fiscal Period Focus Disclosure of detailed information about intangible assets [abstract] Entity Shell Company Warrants purchased. Warrants purchased Concentrations of risk [axis] Net cash flows from (used in) financing activities Cash flows from (used in) financing activities Net cash provided by financing activities Cash advances and loans from related parties Payments to related parties Cybersecurity Risk Management, Strategy, and Governance [Abstract] Court arbitration award against suppliers. Court Arbitration Award Against Suppliers Court arbitration award against supplier Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag] Accounts payable - related parties Current payables to related parties Disclosure of Fair Value of Warrants Issued Using Black Scholes Option Valuation Model [Explanatory] Disclosure of fair value of warrants issued using Black Scholes Option Valuation model. Disclosure of Fair Value of Warrants Issued Using Black Scholes Option Valuation Model Cybersecurity Risk Board of Directors Oversight [Text Block] Lease Insurance Utilities and Government Fees Lease insurance utilities and government fees Lease insurance, utilities and government fees Issue of equity Shares issued for cash Events After Reporting Period Events after Reporting Period [Member] Events after reporting period member. Research And Development Tax Credits Received Research and development tax credits received. Research and development tax credits received Cameron Shaw Cameron Shaw. Cameron Shaw [Member] Total cash Cash Cash Laboratory equipment. Laboratory Equipment Member Laboratory Equipment Former non executive director. Former non Executive Director [Member] Former non-executive Director Number of warrants issued Number of warrants issued Number of warrants issued. Entity Filer Category Series B preferred investment options to purchase ordinary shares Series B preferred investment options to purchase ordinary shares Series B preferred investment options to purchase ordinary shares. Fiscal year ending March 31, 2024 Less Than One Year To January 31, 2027 Every Twenty Five Issued and Outstanding Ordinary Shares [Member] Every twenty five issued and outstanding ordinary shares. Every Twenty Five Issued and Outstanding Ordinary Shares Increase (decrease) through exercise of warrants, equity Warrant exercise Virax Biolabs Group Holdings Ltd. Virax Biolabs Group Holdings Ltd [Member] Virax Biolabs Group Holdings Ltd Number of office spaces leased. Number of office spaces leased Number of office spaces leased Summary of Calculation of Fair Value of Awards using Black-Scholes Option-Pricing Model Affected by Stock Price on Date of Grant as well as Assumptions Summary of Calculation of Fair Value of Awards using Black-Scholes Option-Pricing Model Affected by Stock price on Date of Grant as well as Assumptions Explanatory Summary of calculation of fair value of awards using black-scholes option-pricing model affected by stock price on date of grant as well as assumptions explanatory Jason Davis. Jason Davis [member] Jason Davis Cost of sales Cost of sales Cost of revenue Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] Other Income Expense Net Other Income Expense Net Other income (expense), net Disclosure of reconciliation of changes in intangible assets and goodwill [text block] Summary of Intangible Software Weighted Average Exercise Price, Warrants Beginning balance Weighted Average Exercise Price, Warrants Ending balance Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement Number of shares to be purchased by stock options issued Number of Shares to be Purchased by Stock Options Issued Number of shares to be purchased by stock options issued. Temporary difference, unused tax losses and unused tax credits [axis] Cybersecurity Risk Management Third Party Engaged [Flag] Cash at end of year Cash at beginning of year Total cash and cash equivalents Cash and cash equivalents Profit (loss) from operating activities Operating loss Operating loss Assets [abstract] Assets Disclosure of leases [text block] Leases Geographical [Domain] Disclosure of transactions between related parties [abstract] Comprehensive income Total Comprehensive loss Subscription Receivable Subscription Receivable. Subscription Receivable [member] Capitalized software development costs. Capitalized software development costs Depreciation Depreciation, property, plant and equipment Depreciation, property, plant and equipment Depreciation Amount incurred by entity for provision of key management personnel services provided by separate management entity Consulting fees Private Placement Offering [Member] Private placement offering. Private Placement Offering Disclosure of detailed information about cash and cash equivalents. Disclosure Of Detailed Information About Cash And Cash Equivalents Explanatory Schedule of Cash and Cash Equivalents Weighted average remaining contractual life of outstanding share options 2019 exercisable. Weighted Average Remaining Contractual Life Of Outstanding Share Options 2019 Exercisable Stock Options, Weighted Average Remaining Term (Years), Exercisable Carrying amount [member] Prepaid software subscription Current Prepaid Software Subscription Current prepaid software subscription. Useful life measured as period of time, property, plant and equipment Estimated useful lives Cash Description of accounting policy for determining components of cash and cash equivalents [text block] GBP British Pound United Kingdom, Pounds One of the Officers One of the Officers [member] One of the Officers. Pre-funded warrants to purchase ordinary shares Pre-funded warrants to purchase ordinary shares Pre-funded warrants to purchase ordinary shares. Percentage of purchases Percentage of purchases Percentage of purchases. Currency [Axis] Total lease liabilities Lease liabilities Annual rent Beginning Balance Ending Balance Lease Liabilities Country of incorporation of subsidiary Jurisdiction ViraxVet ViraxVet. Virax Vet [Member] Pre Funded Warrant Termination Date Pre funded warrant termination date. Pre-funded warrant termination date Cybersecurity Risk Management, Strategy, and Governance [Table] Amount of Preferred Investment Option Amount of preferred investment option. Amount of preferred investment option to an investor Total intangible assets other than goodwill Intangible assets other than goodwill Intangible assets other than goodwill at end of period Intangible assets other than goodwill at beginning of period Intangible software, net Intangible assets Expiry Date Range Expiry Date Of Temporary Differences Unused Tax Losses And Unused Tax Credits Expiry Date Period Expiry date of temporary differences unused tax losses and unused tax credits expiry date period. Property, plant and equipment [abstract] Prepaid expenses and deposits Current prepaid expenses and deposits. Current prepaid expenses and deposits Prepaid expenses and deposits Document Shell Company Report Disclosure of non-adjusting events after reporting period [abstract] Subsidiaries [domain] Disclosure of transactions between related parties [line items] Description of accounting policy for foreign currency translation [text block] Foreign currency translation Disclosure of non-adjusting events after reporting period [line items] Income (loss) before income taxes Earnings (loss) for the year Loss before income taxes Revenue Total revenue Revenue Sales Modified strike price. Modified strike price Other Current Other Prepaid Expenses And Deposits Current other prepaid expenses and deposits. Description of accounting policy for segment reporting [text block] Segment information Prepaid Nasdaq fee Prepaid Security Exchange Fee Prepaid security exchange fee. Net cash flows from (used in) operating activities Cash flows from (used in) operating activities Net cash used in operating activities Cash flows used in operating activities Description of expiry date of deductible temporary differences, unused tax losses and unused tax credits Expiry Date Range Total liabilities Liabilities at end of period Liabilities at beginning of period Liabilities Liabilities Liquidity risk [member] Liquidity Risk Summary of Activity Related to Outstanding Warrants Disclosure of activity related to outstanding warrants explanatory Disclosure of activity related to outstanding warrants. Fair Value of the Pre funded Warrants Fair value of the pre-funded warrants. Fair value of the pre-funded Warrants Applicable tax rate Income tax rate Entity Well-known Seasoned Issuer Shanghai Xitu Consulting Co Ltd FKA Shanghai Logico Bioproducts. Shanghai Xitu Consulting Co Ltd FKA Shanghai Logico Bioproducts [Member] Shanghai Xitu Consulting Co., Ltd (FKA- Shanghai Logico Bioproducts) Strike price. Strike price Investors. Investors [Member] Investor Unused tax losses for which no deferred tax asset recognised Unrecognized deferred tax asset from net operating losses Unrecognized deferred tax assets Unrecognized deferred tax assets Classes of current inventories [abstract] Disclosure of disaggregation of revenue from contracts with customers [table] Subscriptions receivable. Subscriptions receivable Subscriptions receivable Increase (decrease) in number of ordinary shares issued Shares issued for cash, shares Additions Additions other than through business combinations, property, plant and equipment Deferred revenue Adjustments for increase (decrease) in deferred income other than contract liabilities Number of pre-funded warrants issued Number of pre-funded warrants issued Number of pre-funded warrants issued. Disclosure of detailed information about accounts receivable. Disclosure Of Detailed Information About Accounts Receivable Explanatory Summary of Accounts Receivable Amendment Flag Amendment Product and Service [Domain] Virax Biolabs Trading B.V. Virax Biolabs Trading B.V. [Member] Virax Biolabs Trading B.V. Less: imputed interest Imputed interest on lease liabilities. Imputed interest on lease liabilities Due to share holder and related party payable. Due to share holder and related party payable Due to share holder and related party payable Disclosure of share capital, reserves and other equity interest [text block] Stockholder's equity Disclosure of detailed information about property, plant and equipment [line items] Issue of equity for services. Shares issued for services Chief Executive Officer [Member] Chief Executive Officer Lease term Lease term. Lease term Disclosure of functional and presentation currency. Disclosure Of Functional And Presentation Currency Explanatory Functional and Presentation Currency Warrants Cancelled Number of other equity instruments forfeited in share-based payment arrangement Disclosure of information about key management personnel [text block] Key management compensation Entity Address, Postal Zip Code Undiscounted operating lease payments to be received Total lease payments Nigel McCracken, Chief Operating Officer and Director Nigel McCracken, Chief Operating Officer and Director. Nigel McCracken, Chief Operating Officer and Director [Member] Categories of related parties [domain] Percentage of Increase in Annual Amount Each Year Percentage of increase in annual amount each year. Percentage of increase in annual amount each year Series A preferred investment options to purchase ordinary shares Series A preferred investment options to purchase ordinary shares Series A preferred investment options to purchase ordinary shares. Schedule of Annual Rent Schedule of annual rent. Schedule of Annual Rent [Table Text Block] Cybersecurity Risk Role of Management [Text Block] Fair value Weighted average fair value at measurement date, share options granted Entity Address, Address Line One New warrants. New Warrants New Warrants [Member] SGD Singapore Dollar Singapore, Dollars Non Controlling Interest Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] James Foster, Chief Executive Officer and Director member. James Foster, Chief Executive Officer and Director [Member] James Foster, Chief Executive Officer and Director Other Income Expense [Abstract] Other income (expense): Later than five years [member] More Than Five Years Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block] Number of shares issued Total number of shares issued Number of shares issued Bonus Key management personnel bonus. Key Management Personnel Bonus Virax immune t cell medical device company limited. Virax Immune T Cell Medical Device Company Limited [Member] Virax Immune T- Cell Medical Device Company Limited Disclosure of income tax [text block] Income tax Purchase price per ordinary share and associated preferred options Purchase price per ordinary share and associated preferred options. Ordinary shares at a purchase price per pre-funded warrant and associated preferred option Offering costs Offering costs. Offering costs Trade and other current receivables [abstract] Document Type Document Type Increase through other contributions by owners, equity PIPE transaction Percentage of entity's revenue Percenatge of revenue Operating expense Total operating expenses Net cash used in investing activities Cash flows from (used in) investing activities Net cash flows from (used in) investing activities Conversion of convertible debt. Conversion of convertible debt Conversion of convertible debt Entity Central Index Key CIK Stock Options, Aggregate Intrinsic Value, Granted Options, Granted, Aggregate Intrinsic Value Options, granted, aggregate intrinsic value. Third party shareholders. Third Party Shareholders [Member] Third Party Shareholders Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block] Commitments [Abstract] Commitments. Credit risk [member] Credit Risk Consulting revenues. Consulting Revenues Bottom of Range Bottom of range [member] Fiona Foster [Member] Fiona Foster Fiona Foster. Yair Erez, Independent Director member. Yair Erez, Independent Director [Member] Yair Erez, Independent Director Geographical areas [axis] Pre-funded warrant exercise Stock Issued During Period Value Pre-funded Warrant Exercise Stock issued during period value pre-funded warrant exercise. Borrowings Total borrowings Borrowings Summary of Lease Liability Activity Disclosure of quantitative information about lease liabilities explanatory. Disclosure of quantitative information about lease liabilities explanatory Major ordinary share transactions [member] Major Ordinary Share Transactions Key management personnel compensation Compensation award Total Stock Options Stock Options [Member] Stock options member. Euro Member Countries, Euro EUR Euro Shares issued for services Increase decrease in number of ordinary shares issued for services. Shares issued for services, shares Accumulated Deficit Schedule of Diluted Loss Per Share Diluted loss per share. Diluted Loss Per Share Explanatory Document Financial Statement Error Correction [Flag] Increase decrease in number of shares issued for rounding on share consolidation. Increase Decrease In Number Of Shares Issued For Rounding On Share Consolidation Shares issued for rounding on Share Consolidation, shares Types of risks [domain] Closing foreign exchange rate Closing rate Maximum exposure to credit risk Maximum credit exposure Proceeds from issue of ordinary shares Gross proceeds Number of customer. Number of customer Total accumulated other comprehensive income Accumulated other comprehensive income Accumulated Other Comprehensive Income (loss) Disclosure of estimated useful lives of property plant and equipment. Disclosure Of Estimated Useful Lives Of Property Plant And Equipment Explanatory Disclosure of Estimated Useful Lives of Property Plant and Equipment Related party transactions [abstract] Current Fiscal Year End Date November Private Placement November Private Placement [Member] November private placement. Proceeds from Exercise of Pre-funded Warrants Proceeds from exercise of pre-funded warrants. Proceeds from exercise of pre-funded warrants Disclosure of subsidiaries [text block] Summary of Consolidated Operating Subsidiaries Prepaid expenses and deposits Adjustments for decrease (increase) in prepaid expenses Disclosure of contingent liabilities [abstract] Disclosure Of Value Added Tax Receivable and Tax Credits Explanatory Disclosure of value added tax receivable and tax credits. VAT Receivable and Tax Credits Stock Options, Grant Date Fair Value, Granted Options Granted, Grant Date Fair Value Options granted, grant date fair value. Entity Address, State or Province Nelson Haight, Independent Director member. Nelson Haight, Independent Director [Member] Nelson Haight, Independent Director Total current liabilities Current liabilities Current liabilities Current liabilities Warrants Warrants [member] Imputed interest for debt Interest expense on debt instruments issued Number Of Office And Lab SpacesLeased. Number Of Office And Lab Spaces Leased Number of office and lab spaces leased Issuance of unregistered warrants to purchase ordinary shares Issuance of unregistered warrants to purchase ordinary shares. Geographical [Axis] Chief Operating Officer [Member] Chief Operating Officer Conversion of class B ordinary shares in to class A ordinary shares. Conversion of Class B Ordinary Shares In to Class A Ordinary Shares Conversion of class B ordinary shares into class A ordinary shares Weighted average remaining contractual life of other equity instuments Weighted average remaining contractual life of other equity instuments. Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price, Warrants Granted Weighted average exercise price of other equity instruments granted in share-based payment arrangement Non-adjusting events after reporting period [axis] Disclosure of trade and other receivables [text block] Summary of VAT Receivable Other comprehensive income, net of tax, exchange differences on translation of foreign operations Other comprehensive income, net of tax, exchange differences on translation of foreign operations Foreign currency adjustment Placement Agent Warrants Placement Agent Warrants [Member] Placement agent warrants. Warrants issued purchase price per share Warrants issued purchase price per share Warrants issued purchase price per share. Non-capital losses available for future period Non-capital losses available for future period Non capital losses available for future period. Non Capital Losses Available For Future Period Non-capital losses available for future period Disclosure of financial risk management [text block] Risk management overview Annual rent on leases. Annual rent on leases Annual rent Virax biolabs uk limited. Virax Biolabs UK Limited [Member] Virax Biolabs (UK) Limited Preferred Investment Options To Purchase Fair Value Preferred investment options to purchase fair value. Preferred investment options to purchase fair value Net proceeds from issue of ordinary shares. Net Proceeds From Issue Of Ordinary Shares Net proceeds Issuance of Warrants to Purchase Shares Fair Value Issuance of warrants to purchase shares fair value. Fair value of warrants issued to purchase shares Forfeiture rate Forfeiture Rate Forfeiture rate. Existing warrants. Existing Warrants [Member] Existing Warrants Accumulated Other Comprehensive Income (Loss) Weighted average exercise price of share options forfeited in share-based payment arrangement Stock Options, Exercise price, Forfeiture Disclosure of temporary difference, unused tax losses and unused tax credits [abstract] Capitalized software member. Capitalized Software [Member] Capitalized Software Capital reserve Reserves Range [axis] Amounts payable, related party transactions Related party transaction payable Total Related Party Payables Number of fractional shares issued. Number of fractional shares issued Exercised Number of share options exercised in share-based payment arrangement Proceeds from issuing other equity instruments Proceeds from PIPE transaction Cash flows from investing activities: Cash flows from (used in) investing activities [abstract] Issued for rounding on share consolidation. Issued For Rounding On Share Consolidation Shares issued for rounding on Share Consolidation Disclosure of risk management strategy related to hedge accounting [table] Stock Options, Exercise price, Exercisable Weighted average exercise price of share options exercisable in share-based payment arrangement Trade and other receivables [abstract] Number of Pre-funded Warrants Exercised Number of pre-funded warrants exercised. Number of pre-funded warrants exercised Additional funds raised to alleviate deficit Additional funds raised to alleviate deficit. Additional Funds Raised to Alleviate Deficit Summary of Prepaid Expenses and Deposits Disclosure Of Prepaid Expenses And Deposits Explanatory Disclosure of prepaid expenses and deposits. Disclosure of terms and conditions of share-based payment arrangement [table] Warrants Granted Number of other equity instruments granted in share-based payment arrangement Earnings per share [abstract] Basic and diluted net loss per share to Virax Biolabs shareholders* Total Stockholders' Equity (Virax) Reduced exercise price. Reduced exercise price Options expired date fair value. Options Expired Date Fair Value Stock Options, Grant Date Fair Value, Expired Number of votes entitled. Number of votes entitled Number of votes entitled Disclosure of property, plant and equipment [text block] Property, plant & equipment, net Comprehensive income, attributable to owners of parent Comprehensive loss attributable to Virax Comprehensive loss attributable to Virax Biolabs shareholders Disclosure of disaggregation of revenue from contracts with customers [text block] Schedule of Disaggregation of Revenue from Contracts with Customers Adjustments for gain on debt extinguishment. Adjustments for gain on debt extinguishment Gain on debt extinguishment Inventory write-down Inventory written off to general and administrative cost Less: Write down of inventories Combined purchase price per pre-funded warrant and one and a half ordinary warrant Combined purchase price per pre-funded warrant and one and a half ordinary warrant Combined purchase price per pre-funded warrant and one and a half ordinary warrant. Details of quantitative information about lease liabilities [Abstract] Details of quantitative information about lease liabilities. Average price Exercise price, share options granted Disclosure of detailed information about property, plant and equipment [text block] Summary of Property, Plant & Equipment, Net Director And Chief Operating Officer [Member] Director and Chief Operating Officer. Director and Chief Operating Officer Auditor Firm ID Two Thousand and Twenty Six Plan [Member] Two thousand and twenty six plan. 2026 Plan Class b ordinary shares. Class B Ordinary Shares [Member] Class B Ordinary Shares Foreign currency (OCI) Foreign Currency OCI Deferred Tax Assets Foreign currency OCI deferred tax assets. Adjustments for increase (decrease) in trade accounts payable Accounts payable and accrued liabilities Products and services [axis] Number of reportable segments1. Number Of Reportable Segments1 Reportable segment Remaining Amortization Period Remaining amortisation period of intangible assets material to entity Tax effect of permanent differences. Tax Effect Of Permanent Differences Permanent Difference Disclosure of reclassifications or changes in presentation [line items] Number of suppliers. Number of suppliers Number of suppliers Revenue Revenue from contracts with customers Revenues Equity and liabilities Total liabilities and shareholders' equity Foreign exchange loss Foreign exchange loss Additions to right-of-use assets Additions Addition of Right-of-use assets Cybersecurity Risk Management Positions or Committees Responsible [Text Block] Trade payables and accrued liabilities. Trade payables and accrued liabilities Trade payables and accrued liabilities Description of accounting policy for recognition of revenue [text block] Revenue recognition Types of risks [axis] Useful life for amortization Amortisation method, intangible assets other than goodwill Document Information [Line Items] Document Information: Adjustments for share-based payments Stock-based compensation Treasury Shares Treasury shares [member] Loan payable Adjustments for decrease (increase) in loans and advances Issuance Of Additional Warrants To Purchase Ordinary Shares Issuance of additional warrants to purchase ordinary shares. Issuance of additional warrants to purchase ordinary shares Amortization To Right of use Assets Amortization To Right of use Assets Amortization Disclosure of quantitative information about right-of-use assets [abstract] Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block] Temporary difference, unused tax losses and unused tax credits [domain] Interest Interest Interest paid, classified as operating activities Disclosure of net deferred tax asset liability. Disclosure of net deferred tax asset liability [table text block] Summary of Net Deferred Tax Asset (Liability) Disclosure of risk management strategy related to hedge accounting [line items] Document Registration Statement Disclosure of maturity analysis of operating lease payments [line items] Number of warrants exercised Number of warrants exercised Number of warrants exercised. Virax Clear Member Virax Clear Virax Clear. ViraxClear Current lease liabilities Lease liabilities, current Description of accounting policy for leases [text block] Leases Total deferred income including contract liabilities Deferred income including contract liabilities Deferred revenue Break date of lease term Break date of lease term. Break date of lease term Classes of share capital [domain] Unfiled current value added tax receivables. Unfiled Current Value Added Tax Receivables Unfiled VAT receivable Unfiled VAT receivable with HMRC Options forfeiture grant date fair value. Options Forfeiture Grant Date Fair Value Stock Options, Grant Date Fair Value, Forfeiture Business Contact [Member] Business Contact Current prepaid clinical trials Current prepaid clinical trials. Prepaid clinical trials Schedule of software development costs. Schedule of software development costs [Table Text Block] Schedule of Software Development Costs Reserves Entity Address, Address Line Two Disclosure of detailed information about intangible assets [line items] Operating expense [abstract]. Operating expenses: Disclosure of terms and conditions of share-based payment arrangement [abstract] Classes of share capital [axis] Types of share-based payment arrangements [domain] Entity Incorporation, Date of Incorporation Date of incoporation Stock issued for services Stock issued for services Stock issued for services. Information on how entity determined whether credit risk of financial instruments has increased significantly since initial recognition Information on how entity determined whether credit risk of financial instruments has increased significantly since initial recognition Share issue related cost Placement agent fees and other offering expenses Warrants Description of accounting policy for warrants [text block] Work-in-process Current work in progress Profit (loss), attributable to owners of parent Net loss attributable to Virax Net loss attributable to Virax Biolabs Shareholders Net loss attributable to Virax Biolabs shareholders Description of accounting policy for fair value measurement [text block] Fair value hierarchy Interest expense on lease liabilities Interest expense on operating lease liabilities Interest expense on lease liabilities Equity attributable to owners of parent Total shareholders' equity (Virax Biolabs) Initial public offering. Initial Public Offering [Member] IPO Key management personnel compensation, other long-term employee benefits Other Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block] Temporary differences [member] Temporary Differences Cybersecurity Risk Management Expertise of Management Responsible [Text Block] Tax Effect Of Expected Income Tax Recovery Tax effect of expected income tax recovery. Expected income tax (recovery) Weighted average share price Average price of shares Disclosure of accounts payable and accrued liabilities explanatory. Disclosure Of Accounts Payable And Accrued Liabilities Explanatory Accounts payable and accrued liabilities Disclosure of events after reporting period [text block] Subsequent Events Number of share options exercisable in share-based payment arrangement Nmber of stock options vested and exercisable Stock Options, Exercisable Issuance of warrants to purchase ordinary shares Issuance of warrants to purchase ordinary shares. Vesting period Share based payment arrangement vesting period. Share Based Payment Arrangement Vesting Period Number of shares surrendered. Number Of Shares Surrendered Surrender of ViraxClear Shares, shares Logico bioproduct corp. Logico Bioproduct Corp [Member] Logico Bioproduct Corp Number of stock options outstanding Stock Options, Ending balance Beginning balance Number of share options outstanding in share-based payment arrangement Entity Address, City or Town Later than three years and not later than four years [member] To January 31, 2030 Shares issued for settlement of related party payable. Shares issued for settlement of related party payable Shares issued for settlement of related party payable Shares issued for settlement of related party payable VAT receivable Current value added tax receivables Total VAT receivable Disclosure of reclassifications or changes in presentation [table] Existing warrants purchased exercised as cash. Existing warrants purchased exercised as cash Deferred Revenue Deferred Revenue Explanatory Deferred revenue explanatory. Total non-current assets Non-current assets Security Exchange Name Issue of equity for settlement of related party payable. Shares issued for settlement of related party payable shares Disclosure of temporary difference, unused tax losses and unused tax credits [table] Virax clear and virax care. ViraxClear and ViraxCare Revenue Contact Personnel Name Adjustments for decrease (increase) in trade accounts receivable Accounts payable - related parties Total intangible assets and goodwill Intangible assets and goodwill Ending balance Beginning balance Net Book Value Intangible assets under development description. Intangible assets under development description Intangible Assets Under Development Supplier information. Supplier information Supplier information Disclosure of classes of share capital [line items] Reclassification of General and administrative expenses to Research and Development expenses Amount of reclassifications or changes in presentation Statement of changes in equity [abstract] Profit (loss) Net Loss Net loss Net loss Loss for the year Net impairment loss (reversal of impairment loss) recognised in profit or loss, trade receivables Impairment loss (reversal of impairment loss) recognised in profit or loss, trade receivables Less: provision for impairment of account receivables Remaining contribution to reserves Contribution to Reserves for Settlement of Related Party Payables Contribution to reserves for settlement of related party payables. Contributed capital - settlement of related party debt Foreign exchange gain Key management compensation. Key management compensation [abstract] Life of warrants to purchase ordinary shares Life of warrants to purchase ordinary shares. Life of warrants to purchase ordinary shares Prepaid directors and officers insurance Prepaid directors and officers insurance. Reconciliation of accounting profit multiplied by applicable tax rates [abstract] Document Period End Date Period End Date Title and Position [Axis] ICFR Auditor Attestation Flag Categories of related parties [axis] Amortization of Right of Use Assets Amortization of right of use assets. Amortization of right-of-use assets Nigel McCracken Nigel McCracken [Member] Nigel McCracken. Disclosure of non-adjusting events after reporting period [table] Maximum amount to be utilized on loss carryforward in future years Maximum amount to be utilized on loss carryforward in future years. Maximum amount to be utilized on loss carryforward in future years Description of accounting policy for basis of preparation. Description Of Accounting Policy For Basis Of Preparation Explanatory Basis of preparation Disclosure of maturity analysis of operating lease payments [table] Current finished goods Finished goods Right-of-use assets Beginning Balance Ending Balance Right-of-use assets, net Related Parties Total for all related parties [member] Combined purchase price per ordinary share and one and a half ordinary warrant Combined purchase price per ordinary share and one and a half ordinary warrant Combined purchase price per ordinary share and one and a half ordinary warrant. Number of shares authorised Grant of options and shares permits and available for issuance Number of shares authorised Total issued capital Issued capital Issued capital Ordinary shares, $0.01 par value, 2,000,000 shares authorized; 579,218 and 173,679 issued and outstanding as of March 31, 2026 and 2025, respectively Other Income Expenses Other Income Expenses Total other income (expense), net Virax Biolabs USA Management, Inc. Virax Biolabs USA Management, Inc. [Member] Virax Biolabs USA Management, Inc. Total income tax expense (recovery) Provision for profit tax Income tax expense Income tax benefit Details of quantitative information about lease liabilities. Details of quantitative information about lease liabilities [Table] Non-capital losses available for future period - finite Non-capital losses available for future period - finite Non-capital losses available for future period - finite Non Capital Losses Available For Future Period Finite Lived Non capital losses available for future period finite lived. Deferred revenue Total Deferred Revenue Total Deferred Revenue Contract liabilities Contract liabilities at end of period Contract liabilities at beginning of period Hk co. HK co [member] HKCo Purchase price per pre-funded warrant and associated preferred options Purchase price per pre-funded warrant and associated preferred options Purchase price per pre-funded warrant and associated preferred options. Cybersecurity Risk Management, Strategy, and Governance [Line Items] Non-cash compensation expense allocated between general and administrative and research and development expenses. Non-cash compensation expense allocated between general and administrative and research and development expenses Non-cash compensation expense allocated between general and administrative and research and development expenses Number of warrants cancelled Number of warrants cancelled Number of warrants cancelled. Products and services [domain] Depreciation on deferred tax assets. Depreciation on deferred tax assets Depreciation Deletions To Lease Liabilities Deletions to lease liabilities. Deletions Disclosure of temporary difference, unused tax losses and unused tax credits [text block] Summary of Temporary Differences Dividend yield Expected dividend as percentage, share options granted All Currencies [Domain] Disclosure of reclassifications or changes in presentation [abstract] Monthly lease payment. Monthly Lease Payment Monthly lease payment Profit (loss) from continuing operations Profit (loss) from continuing operations Assessable profit Disclosure of detailed information about borrowings [table] Cashless warrant exercise, shares Stock Issued During Period Shares Cashless Warrant Exercise Stock issued during period shares cashless warrant exercised. Cashless warrant exercise Entity File Number Underwriting discounts and commissions Total fee and commission expense Fee and commission expense Lab Space Lab space. Lab Space [Member] Cover [Abstract] Cover Disclosure of general information about financial statements [text block] General information Other comprehensive income, net of tax, exchange difference on translation attributable to owners of parent Foreign currency adjustment Other comprehensive income, net of tax, exchange difference on translation attributable to owners of parent. Effects of currency translation right of use assets. Effects of currency translation right of use assets. Effects of currency translation Effects of currency translation Supplier Concentration of Risk [Member] Supplier concentration of risk. Supplier Concentration Risk Concentrations of risk [domain] Disclosure of quantitative information about right-of-use assets [line items] Change in Presentation Description of Accounting Policy for Change in Presentation Explanatory Description of accounting policy for change in presentation explanatory. SINGAPORE Singapore Description of accounting policy for employee benefits [text block] Employee benefits Cost of inventories recognised as expense during period Inventories expensed to cost of revenue Currency risk [member] Foreign Exchange Risk Other comprehensive income [abstract] Other comprehensive income (loss): Lease security deposit. Lease Security Deposit Security deposit Virax Biolabs FZ-LLC. Virax Biolabs FZ-LLC [Member] Virax Biolabs FZ-LLC Disclosure of related party [text block] Related party transactions Current liabilities [abstract] Current liabilities: Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] Raw materials Current raw materials Deposits Current Deposits Current deposits. 2024 Plan Two Thousand and Twenty Four Plan [Member] 2024 Plan. Virax biolabs group limited. Virax Biolabs Group Limited [Member] Virax Biolabs Group Limited Classes of entity's own equity instruments [domain] Summary of Status of Outstanding Stock Options and Changes Disclosure of number and weighted average exercise prices of share options [text block] Monthly rent on leases Monthly rent on leases. Monthly rent on leases Borrowings [abstract] Counterparties [domain] Disclosure of earnings per share [text block] Loss per share Sales of Test Kits in ViraxVet Sales of Test Kits in ViraxVet. Sales of Test Kits in Virax Vet [Member] Net deferred tax liability (asset) Deferred tax liability (asset) at end of period Deferred tax liability (asset) at beginning of period Deferred tax liability (asset) Deferred Tax Assets (liabilities) Net deferred tax asset (liability) Number of shares outstanding Number of shares, beginning balance Number of shares, ending balance Number of shares outstanding Adjustments for decrease (increase) in inventories Inventories Additions to lease liabilities. Additions to lease liabilities Additions Disclosure of terms and conditions of share-based payment arrangement [line items] Share Consolidation Share consolidation. Share consolidation [Member] Increase (decrease) through net exchange differences, property, plant and equipment Effects of currency translation Description of accounting policy for principles of consolidation. Description Of Accounting Policy For Principles Of Consolidation Explanatory Principles of consolidation Proportion of ownership interests held by non-controlling interests Ownership Later than one year and not later than two years [member] To January 31, 2028 Lease service costs. Lease service costs Lease service costs Summary of significant accounting policies. Summary Of Significant Accounting Policies [Abstract] Foreign exchange gain (loss) Net foreign exchange gain (loss) Foreign currency gain (loss), net Cybersecurity Risk Management Processes Integrated [Flag] Risk-free interest rate Risk free interest rate, share options granted Document Transition Report Stock Options, Weighted Average Remaining Term (Years), Granted Weighted Average Remaining Contractual Life of Share Options, Granted Weighted average remaining contractual life of share options granted. Description of accounting policy for financial instruments [text block] Financial Instruments Profit or loss [abstract] Statement of financial position [abstract] Disclosure of revenue from contracts with customers [text block] Revenue from contracts with customers Gross profit Gross profit Gross profit (loss) Ordinary shares issued price per share. Ordinary Shares Issued Price Per Share Ordinary shares issued price per share Description of accounting policy for share capital and reserves. Description Of Accounting Policy For Share Capital And Reserves Explanatory Share capital and reserves Current assets: HONG KONG Hong Kong Classes of assets [domain] Stock Options, Exercise price, Granted Weighted average exercise price of share options granted in share-based payment arrangement Classes of entity's own equity instruments [axis] Components of equity [axis] Mr Patrick Foster Father Of Mr James Foster. Mr Patrick Foster Father Of Mr James Foster [Member] Mr. Patrick Foster, father of Mr. James Foster Options exercisable grant date fair value. Options Exercisable Grant Date Fair Value Stock Options, Grant Date Fair Value, Exercisable Total basic earnings (loss) per share Basic earnings (loss) per share Basic net loss per share - Ordinary shares Basic loss per share Cybersecurity Risk Management Processes Integrated [Text Block] Average foreign exchange rate Average rate Weighted Average Remaining Contractual Life (Years), Warrants exercisable Weighted average remaining contractual life of other equity instuments vested and exercisable Weighted average remaining contractual life of other equity instuments vested and exercisable. Logico Shanghai. Logico Shanghai [Member] Logico Shanghai Disclosure of monetary assets and liabilities denominated in foreign currencies. Disclosure of Monetary Assets and Liabilities Denominated In Foreign Currencies Explanatory Disclosure of Monetary Assets and Liabilities Denominated In Foreign Currencies Shanghai xitu consulting co limited. Shanghai Xitu Consulting Co Limited [Member] Shanghai Xitu Consulting Co., Limited Description of accounting policy for accounts receivable. Description Of Accounting Policy For Accounts Receivable Explanatory Accounts receivable Description of accounting policy for property, plant and equipment [text block] Property plant and equipment Accrued payroll taxes Accrued Payroll Tax Accrued payroll tax. Current trade receivables Accounts receivable Current Accounts receivables Class A Class A Class A Shares Maturity [domain] Inventory Inventories Inventories, net Inventories, net Disclosure of effect of changes in foreign exchange rates [text block] Disclosure of Effect of Changes in Foreign Exchange Rates Virax Biolabs Group Limited Virax biolabs limited. Virax Biolabs Limited [Member] Virax Biolabs Limited Document Fiscal Year Focus Adjustments for losses (gains) on disposal of non-current assets Loss on disposal of property, plant & equipment Maximum percentage of taxable income to be utilized in future years. Maximum percentage of taxable income to be utilized in future years Maximum percentage of taxable income to be utilized in future years Ordinary Shares Ordinary shares [member] Maturity [axis] Dilutive shares Potentially dilutive ordinary shares Dilutive effect of share options on weighted average number of ordinary shares Ordinary shares Weighted average number of ordinary shares used in calculating basic earnings per share Weighted average number of ordinary shares used in basic and diluted loss per share (Ordinary shares) Jason Davis Former Chief Financial Officer [Member] Jason davis former chief financial officer. Jason Davis, Former Chief Financial Officer Geographical areas [domain] Disclosure of contingent liabilities [table] Purchaser Purchaser [Member] Purchaser. 2023 Plan Two Thousand and Twenty Three Plan [Member] 2023 plan member]. Net change in cash Net increase (decrease) in cash and cash equivalents after effect of exchange rate changes Increase (decrease) in cash and cash equivalents after effect of exchange rate changes Net decrease in cash Purchase of internally developed software classified as investing activities. Purchase of internally Developed Software Classified As Investing Activities Investment - internally developed software Investment - internally developed software Weighted Average Remaining Contractual Life Of Other Equity Instuments Granted Weighted average remaining contractual life of other equity instuments granted. Weighted Average Remaining Contractual Life (Years), Granted Description of accounting policy for impairment of financial assets [text block] Impairment of assets Disclosure of temporary difference, unused tax losses and unused tax credits [line items] Non-current liabilities: Non-current liabilities [abstract] Weighted Average Exercise Price, Warrants Cancelled Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement Subsidiaries [axis] Gross carrying amount [member] Cost Warrants Exercised Number of other equity instruments exercised or vested in share-based payment arrangement Proceeds from issuing shares Proceeds from shares issuance for cash Net proceeds Supplemental disclosure of cash flow information. Supplemental disclosure of cash flow information [abstract] Supplemental disclosure of cash flow information Services. Services [Member] Services Maximum percentage of current year profit utilized on loss carryforward. Maximum percentage of current year profit utilized on loss carryforward Maximum percentage of current year profit utilized on loss carryforward Number of rooms leased. Number of rooms leased Number of rooms leased Prepaid vendor products Current Prepaid vendor products Current prepaid vendor products. Description of share consolidation. Description of share consolidation Counterparties [axis] Stock Options, Forfeiture and cancelled Number of share options forfeited in share-based payment arrangement Stock options, forfeiture Stock Options, Forfeiture Stock Options, Forfeited Depreciation expense Depreciation expense Depreciation Cash flows from (used in) financing activities [abstract] Cash flows from financing activities: Disclosure of accounting judgements and estimates [text block] Critical Estimates and Judgments Initial Annual Amount on Leases Initial annual amount on leases. Initial annual amount Intangible Software, net Disclosure of intangible assets [text block] Description of accounting policy for income tax [text block] Income tax Range [domain] Statement of changes in equity [line items] Non-cash compensation expense (included in general and administrative expense) Non-Cash Compensation Expense (Included in General and Administrative Expense) Non-cash compensation expense (included in general and administrative expense). Balance Total property, plant and equipment Property, plant and equipment Balance Balance Balance Property, plant & equipment, net Title of 12(b) Security Operating lease agreement term. Operating Lease Agreement Term Operating lease agreement term Stock Options, Granted Options issued Number of share options granted in share-based payment arrangement Tax effect of provision to net operating losses. Tax Effect Of Provision To Net Operating Losses Provision to NOLs Lease insurance. Lease insurance Lease insurance Current debt instruments issued Loan payable Pre-funded warrant exercise, shares Stock Issued During Period Shares Pre-funded Warrant Exercise Stock issued during period shares pre-funded warrant exercise. Disclosure of disaggregation of revenue from contracts with customers [line items] Disclosure of borrowings [text block] Loan Payable Document Information [Table] Document Information Details of quantitative information about lease liabilities. Details of quantitative information about lease liabilities [line items] Later than two years and not later than three years [member] To January 31, 2029 Disclosure of contingent liabilities [line items] Authorized share capital. Authorized share capital Authorized share capital Fixtures and fittings [member] Furniture & Fixtures Impairment loss recognised in profit or loss, intangible assets other than goodwill Impairment loss recognised in profit or loss, intangible assets other than goodwill Impairment of intangible asset Related party compensation for Officers and Directors text block Related Party Compensation for Officers and Directors [Text Block] Summary of Related Party Compensation for Officers and Directors Profit (loss), attributable to non-controlling interests Net loss attributable to non-controlling interest Net loss attributable to non-controlling interest Trading Symbol Lab equipment member. Lab Equipment [Member] Lab Equipment Number of share options expired in share-based payment arrangement Stock Options, Expired Number of stock options expired Weighted average ordinary shares used in calculating basic and diluted earnings per share [abstract] Basic and diluted weighted average shares outstanding Pension and Related Expenses Pension and related expenses. Pension and related expenses Type of Intangible Asset Type of intangible asset. Type of intangible asset Entity Ex Transition Period Share price per share. Share price per share Share price per share Deposit on leases Deposit on leases. Deposit on leases Existing warrants Existing warrants. Existing Warrants VAT receivable Adjustments for decrease increase in VAT receivable. Adjustments for Decrease Increase In VAT Receivable Disclosure of classes of share capital [table] Warrants exercisable Number of other equity instruments exercisable in share-based payment arrangement Accumulated depreciation and amortisation [member] Accumulated Depreciation Accumulated Amortization Weighted Average Exercise Price, Warrants exercisable Weighted Average Exercise Price, Ending balance Weighted average exercise price of other equity instruments exercisable in share-based payment arrangement Address Type [Domain] Stock Options, Grant Date Fair Value, Outstanding Options Outstanding, Grant Date Fair Value Options outstanding, grant date fair value. Stock Options, Grant Date Fair Value, Outstanding Beginning Balance Stock Options, Grant Date Fair Value, Outstanding Ending Balance Document Annual Report Right-of-use assets, net Right-of-use assets, net Equity [abstract] Virax Biolabs Shareholders' equity Singapore co. Singapore Co [Member] SingaporeCo Disclosure of detailed information about intangible assets [table] Document Accounting Standard Class A Ordinary Shares [Member] Class a ordinary shares. Class A Ordinary Shares Disclosure of commitments [text block] Commitments Total assets Assets at end of period Assets at beginning of period Assets Adjustments for unrealised foreign exchange losses (gains) Foreign currency translation (gain) loss Entity Addresses, Address Type [Axis] Cash and cash equivalents [abstract] Contract liabilities [abstract] Date of end of reporting period of financial statements of subsidiary Incorporation Date Warrants outstanding, Ending balance Warrants outstanding, Beginning balance Number of other equity instruments outstanding in share-based payment arrangement Disclosure of transactions between related parties [text block] Summary of Related Party Payables Total trade and other current receivables Trade and other current receivables Owing amount Cashless warrant exercise Stock Issued During Period Value Cashless Warrant Exercise Stock issued during period value cashless warrant exercise. Components of equity [domain] Types of share-based payment arrangements [axis] Boustead Securities, LLC Boustead securities, llc. Boustead Securities, LLC [Member] Warrant exercise price. Warrant exercise price Losses and unutilized capital allowances carried back period. Losses and unutilized capital allowances carried back period Losses and unutilized capital allowances carried back period Par value per share Par value Par value per share Stock Options, Exercise price, Ending balance Stock Options, Exercise price, Beginning balance Weighted average exercise price of share options outstanding in share-based payment arrangement Disclosure of cash and cash equivalents [text block] Cash and cash equivalents Contact Personnel Email Address Description of accounting policy for accounts payables and accrued liabilities. Description Of Accounting Policy For Accounts Payables And Accrued Liabilities Explanatory Accounts payables and accrued liabilities Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block] Open tax years Open Tax Years Open tax year Disclosure of quantitative information about right-of-use assets [table] Disclosure of maturity analysis of operating lease payments [text block] Schedule of Commitments for Minimum Lease Payments Summary of Maturity of Lease Liabilities Diluted ordinary shares Weighted average number of ordinary shares used in calculating diluted earnings per share Weighted average number of ordinary shares and potential ordinary shares used as the denominator in calculating diluted loss per share Non-current assets [abstract] Non-current assets Interest expense Interest expense, net Interest expense Current trade payables Accounts payable Key management personnel salary. Key Management Personnel Salary Salary Total diluted earnings (loss) per share Diluted earnings (loss) per share Diluted net loss per share - Ordinary shares Diluted loss per share Weighted average exercise price of share options expired in share-based payment arrangement Stock Options, Exercise price, Expired Disclosure of detailed information about borrowings [line items] Entity Registrant Name Registrant Name Entity Voluntary Filers Statement of changes in equity [table] Virax Biolabs UK Operating Limited. Virax Biolabs UK Operating Limited [Member] Virax Biolabs UK Operating Limited Virax Biolabs UK Operating LLC James Foster. James Foster [Member] James Foster Cybersecurity Risk Management Positions or Committees Responsible [Flag] Disclosure of financial assets [line items] Adjustments for other expense. Adjustments for Other Expense Other expense Payment of loan Payment of loan. Total payments for loan Treasury shares Treasury shares Treasury shares Accounts receivable. Accounts receivable [abstract] Effects of currency translation lease liabilities. Effects of currency translation lease liabilities Effects of currency translation Gross proceeds from issue of private placement Gross proceeds from issue of private placement Gross proceeds from issue of private placement. Entity Common Stock, Shares Outstanding Accrued interest expense. Accrued Interest Expense Accrued interest Losses and unutilized capital allowances carried back subject to cap. Losses and unutilized capital allowances carried back subject to cap Losses and unutilized capital allowances carried back subject to cap Preferred Investment Options To Purchase Ordinary Shares Preferred investment options to purchase ordinary shares. Preferred investment options to purchase ordinary shares Note payable Note Payable Note payable. Total stockholders' equity Equity Equity, beginning balance Equity, ending balance Total shareholders' equity attributable to Virax Biolabs ordinary shareholders Evan Norton, Independent Director member. Evan Norton, Independent Director [Member] Evan Norton, Independent Director Issued for settlement of debt. Issued For Settlement Of Debt Shares issued for settlement of debt Disclosure of number of share issued in various entities. Disclosure Of Number Of Share Issued In Various Entities Explanatory Schedule of Number of Shares Issued Commitment and contingencies. Commitment and contingencies (Note 15) Current accounts payable and accrued liabilities. Current accounts payable and accrued liabilities Accounts payable and accrued liabilities AP and Accrued Liabilities Total accounts payable and accrued liabilities Classes of property, plant and equipment [domain] Weighted Average Exercise Price, Warrants Exercised Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement Stock Options, Aggregate Intrinsic Value, Outstanding Options, Outstanding, Aggregate Intrinsic Value Options, outstanding, aggregate intrinsic value. Balances with banks Cash at bank Reduction of issued capital Surrender of ViraxClear Shares Sales of Test Kits in ViraxClear Sales of test kits in ViraxClear. Sales of Test Kits in Virax Clear [Member] Incremental fair value of warrants recognized. Incremental Fair Value Of Warrants Recognized Incremental fair value of warrants recognized Iain Miller Independent Director [Member] Iain Miller independent director. Iain Miller, Independent Director General and administrative expense General and administrative General and administrative expenses Tax effect of expense not deductible in determining taxable profit (tax loss) Change in unrecognized deductible temporary differences Change in unrecognized deductible temporary differences Total retained earnings Retained earnings Accumulated deficit Accumulated deficit Logico Bioproducts Corp. Logico Bioproducts Corp [Member] Logico Bioproducts Corp. Number of shares issued for conversion of convertible debt. Number Of Shares Issued For Conversion Of Convertible Debt Shares issued for conversion of convertible debt. shares Disclosure of detailed information about accounts payable and accrued liabilities. Disclosure Of Detailed Information About Accounts Payable And Accrued LiabilitiesExplanatory Schedule of Accounts Payable and Accrued Liabilities Trade receivables Accounts receivable from customers Net account receivables Net account receivables Equity and liabilities [abstract] Liabilities Computer equipment [member] Computer Equipment Title and Position [Domain] Disclosure of detailed information about property, plant and equipment [table] Disclosure of reconciliation of income taxes at statutory rates. Disclosure of reconciliation of income taxes at statutory rates [Table text block] Reconciliation of Income Taxes at Statutory Rates City Area Code Disclosure of maturity analysis of operating lease payments [abstract] Auditor Name Surrender amount due. Surrender amount due Surrender amount due Stock Options, Grant Date Fair Value, Forfeiture and cancelled Options Forfeiture and Cancelled, Grant Date Fair Value Options forfeiture and cancelled, grant date fair value. Purchase of property, plant and equipment, classified as investing activities Purchase of property, plant & equipment Increase decrease in number of ordinary shares issued for settlement of related party payable. Shares issued for settlement of related party payable, shares Research and development expense Research & Development Research & development Disclosure of information about inventories. Disclosure of information about inventories Explanatory Summary of Inventories Statement of cash flows [abstract] Increase decrease through exercise of warrants equity, shares. Increase Decrease Through Exercise Of Warrants Equity Shares Warrant exercise, shares Description of functional currency Functional Currency Class B shares. Class B Class B Shares Disclosure of inventories [text block] Inventories Share based payment Option Awards Key management personnel compensation, share-based payment Fixed interest rate Borrowings, interest rate Classes of assets [axis] November ordinary warrants. November Ordinary Warrants November Ordinary Warrants [Member] Proceeds from exercise of warrants Net proceeds from exercise of warrants Proceeds from warrant exercise Non-adjusting events after reporting period [domain] Non-controlling interests Non-Controlling Interest Cash flows from (used in) operating activities [abstract] Cash flows from operating activities: Virax Biolabs Limited FKA Shanghai Biotechnology Devices Ltd. Virax Biolabs Limited FKA Shanghai Biotechnology Devices Ltd [Member] Virax Biolabs Limited (FKA- Shanghai Biotechnology Devices Ltd) March Private Placement March Private Placement [Member] March private placement. Expected volatility Expected volatility, share options granted Entity Address, Country Non-current trade receivables Accounts receivable Operating lease agreement commencement date. Operating Lease Agreement Commencement Date Operating lease agreement commencement date Every Ten Issued and Outstanding Ordinary Shares Every Ten Issued and Outstanding Ordinary Shares [Member] Every Ten Issued and Outstanding Ordinary Shares [Member] Description of accounting policy for measuring inventories [text block] Inventories Exercise of overallotment option to purchase ordinary shares. Exercise of Overallotment Option to Purchase Ordinary Shares Exercise of overallotment option to purchase ordinary shares Increase decrease in number of shares issued for settlement of debt. Increase Decrease In Number Of Shares Issued For Settlement Of Debt Shares issued for settlement of debt, shares Earnings per share [text block] Schedule of Loss Per Share Provision for profit tax. Provision for profit tax Provision Total comprehensive income, attributable to non-controlling interests Comprehensive income, attributable to non-controlling interests Comprehensive loss attributable to non-controlling interest Adjustments for increase decrease in operating assets and liabilities. Adjustments for increase decrease in operating assets and liabilities [abstract] Net changes in operating assets & liabilities: Prepaid Expenses And Deposits Abstract Prepaid expenses and deposits. Virax cayman. Virax Cayman [Member] Virax Cayman Accretion expense Adjustments for accretion expense. Adjustments for accretion expense Disclosure of disaggregation of revenue from contracts with customers [abstract] Auditor Location Issue of convertible instruments Transfer of Class B to Class A Issue of convertible instruments Accounting judgements and estimates. Accounting Judgements And Estimates [Abstract] Subclassifications of assets, liabilities and equities [abstract] Major components of tax expense (income) [abstract] Deferred Tax Assets (liabilities) Deferred tax assets Deferred tax assets Deferred Tax Assets (liabilities) Total cash equivalents Cash equivalents Consideration paid (received) Consideration paid (received) Disclosure of transactions between related parties [table] Entity Interactive Data Current Impairment Impairment loss recognised in profit or loss, intangible assets and goodwill Impairment loss recognised in profit or loss, intangible assets and goodwill Impairment of intangible asset Increase (decrease) through conversion of convertible instruments, equity Shares issued for conversion of convertible debt Changes in deferred tax liability (asset) [abstract] Deferred Tax Assets (liabilities) Tax effect of foreign tax rates Change in statutory, foreign tax, foreign exchange rates and other Total depreciation and amortisation expense Depreciation and amortisation expense Depreciation and amortisation expense Depreciation and amortization Prepaid Expenses and Deposits Disclosure of prepayments and other assets [text block] Ordinary shares conversion basis. Ordinary shares conversion basis Ordinary shares conversion basis Disclosure of quantitative information about right-of-use assets [text block] Summary of Right of Use Assets Activity Disposals, property, plant and equipment Disposals, property, plant and equipment Disposals Presentation of leases for lessee [abstract] Disclosure of classes of share capital [abstract] Issued capital [member] Ordinary Shares Ordinary shares Later than four years and not later than five years [member] To January 31, 2031 Cashless warrants exercised in exchange for shares Cashless warrants exercised in exchange for shares Cashless warrants exercised in exchange for shares. One to Five Years Later than one year and not later than five years [member] Stock Options, Weighted Average Remaining Term (Years), Outstanding Weighted average remaining contractual life of outstanding share options Interest expense Interest expense on borrowings Local Phone Number Virax biolabs pte limited. Virax Biolabs Pte Limited [Member] Virax Biolabs Pte. Limited CHINA China Auditor Opinion [Text Block] Auditor Opinion incremental borrowing rate incremental borrowing rate. incremental borrowing rate Increase (decrease) through transfer to statutory reserve, equity Imputed interest Supplemental disclosure of non cash investing and financing activities. Supplemental disclosure of non cash investing and financing activities [abstract] Supplemental disclosure of non-cash investing and financing activities: China, Yuan Renminbi RMB Renminbi Customer Concentrations Risk [Member] Customer concentrations risk. Customer Concentrations Risk Customer Concentration Risk Disclosure of risk management strategy related to hedge accounting [abstract] ViraxImmune T-Cell Medical Device Company Limited (FKA- Stork Nutrition Asia Limited) Virax Immune T Cell Medical Device Company Limited FKA Stork Nutrition Asia Limited. Virax Immune T Cell Medical Device Company Limited FKA Stork Nutrition Asia Limited [Member] Stock-based compensation Total employee benefits expense Employee benefits expense Employee benefits expense Inducement Letter Inducement letter. Inducement Letter [Member] Adjustments to reconcile profit (loss) [abstract] Adjustments to reconcile net loss to net cash used in operating activities: Accounts receivable Disclosure of accounts receivable. Disclosure Of Accounts Receivable Explanatory Current accrued liabilities. Current Accrued Liabilities Accrued liabilities Total current assets Current assets Summary of Deferred Revenue Summary of Deferred Revenue Explanatory Summary of deferred revenue explanatory. Old Shanghai Lease Old Shanghai lease. Old Shanghai lease [Member] Information about major customers Customer information Pre Funded Warrants [Member] Pre funded warrants. Pre-Funded Warrants Disclosure of detailed information about leases. Disclosure of detailed information about leases [table] Entity Emerging Growth Company Shares for Conversion of Convertible Debt Reserve of equity component of convertible instruments [member]